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William B. White, MD*An elevation of blood pressure (BP) in the systemic
circulation (hypertension) is the most common car-
diovascular condition in the general population and
considered to be the most ubiquitous cardiovascular
risk factor in competitive athletes. Competitive ath-
letes include those athletes involved in organized
sports that typically occur in schools, communities,
and professional leagues, including but not limited
to intramural and league sports in which medical
supervision is typically required. Although most
competitive athletes are between the ages of 20 and
40 years, many younger people now participate incompetitive athletics. The 2013 update from the
American Heart Association using the National Health
and Nutrition Examination (NHANES) data from 2007
to 2010 estimates that 9.1% of men aged 20 to 34 years
and 6.7% of women of that age are hypertensive,
based on having an elevated BP measurement or
answering “yes” to the question, “Are you taking
antihypertensive medication or were you told that
you had hypertension?” (1) The prevalence in children
and adolescents is estimated to bez3.5%, with higher
percentages in older and obese children (2). The
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TABLE Guidelines for Clinic (or Ofﬁce) BP Measurement
Posture
BP obtained in the seated position is recommended. The subject should sit
quietly for 5 min, with the back supported in a chair, with feet on the ﬂoor
and the arm supported at the level of the heart, before BP is recorded.
Circumstances
No caffeine should be ingested during the hour preceding the reading, and no
smoking during the 30 min preceding the reading.
A quiet, warm setting should be available for BP measurements.
Equipment
Cuff size
The bladder should encircle and cover at least 80% of the length of the arm;
if it does not, use a larger cuff. If bladder is too short, misleadingly high
readings may result.
Manometer
Use a validated electronic (digital) device, a recently calibrated aneroid or
mercury column sphygmomanometer.
Technique
Number of readings
On each occasion, take at least 2 readings, separated by as much time as is
practical. If readings vary by >10 mm Hg, take additional readings until 2
consecutive readings are within 10 mm Hg.
If the arm pressure is elevated, take the measurement in 1 leg to rule out
aortic coarctation (particularly in patients <30 y of age).
Initially, take pressures in both arms; if the blood pressures differ, use the
arm with the higher pressure.
If the initial values are elevated, obtain 2 other sets of readings at least
1 wk apart.
Performance
Inﬂate the bladder quickly to a pressure 20 mm Hg above the systolic BP, as
recognized by the disappearance of the radial pulse; deﬂate the bladder
at 2 mm Hg/s.
Record the Korotkoff phase I (appearance) and phase V (disappearance)
sounds. If the Korotkoff sounds are weak, have the patient raise the arm,
then open and close the hand 5–10 times, and then reinﬂate the bladder
quickly.
BP indicates blood pressure.
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2394having an elevated BP at or above certain levels measured
by routine sphygmomanometry under appropriate con-
ditions on at least 2 separate occasions separated by at
least 1 week (3). However, BP measurements in the
competitive athlete are typically obtained by different
healthcare providers, which makes it particularly neces-
sary that the testing conditions be standardized before
the diagnosis of hypertension is made. People >18 years
of age with a BP >140 mm Hg systolic and/or >90 mm Hg
diastolic are considered to have hypertension (3). In
children and adolescents, hypertension is deﬁned as
average systolic or diastolic BP levels greater than the
95th percentile for sex, age, and height; however, earlier
physical maturation of the competitive athlete leaves
open to question when an adult age criterion for hyper-
tension should be applied to the adolescent (4). In
determining the level of competitive athletic activity that
a hypertensive person may engage in, it is also important
to determine the degree of hypertension-related target-
organ damage. Although hypertension has been associ-
ated with an increased risk for complex ventricular
arrhythmias and sudden death, this cardiovascular risk
factor per se has not been implicated in sudden death in
young competitive athletes (5). For the general popula-
tion, increased levels of noncompetitive recreational
physical activity are generally regarded as beneﬁcial.
With physical activity, BP typically falls, the incidence of
hypertension drops (6,7), and protection against stroke is
afforded (8). Those who are hypertensive derive protec-
tion from both all-cause and cardiovascular mortality by
maintaining higher levels of cardiorespiratory ﬁtness (9).
ASSESSMENT OF BP
BP should be accurately measured in all people who wish
to participate in competitive athletics before they begin
training. BP should be measured by standard techniques,
using the guidelines listed in the Table. It is common in
young athletes to have their BP measured with an inap-
propriately sized BP cuff because of their often larger
(>33 cm) midarm circumference. In these people, BP
measured this way is often spuriously increased and re-
sults in unnecessary referrals to clinicians for evaluation
and consideration of antihypertensive therapy. Also, there
are often discrepancies between in-ofﬁce and out-of-ofﬁce
BP measurements. For example, elevations induced by
anxiety related to the medical examination are seen in
young people concerned about the potential negative
consequences of the examination. Anxiety-related BP el-
evations may be marked by elevations in heart rate, which
further complicates the interpretation of the physical ex-
amination ﬁndings. In such instances, it is advisable to
obtain unbiased and more comprehensive information
through the use of 24-hour ambulatory BP monitoring.In some people, extremely high BPs may occur on a single
measurement. In this type of patient, ambulatory BP
monitoring would help to further stratify the athlete’s risk
of hypertension at present or in the future if borderline
values were obtained. Ambulatory BP measurement in
people with elevated exercise BP values improves the
prediction of left ventricular hypertrophy (LVH) by echo-
cardiography and development of sustained hypertension
according to 1 study with an 8-year follow-up (10).
EVALUATION
All people who are diagnosed as hypertensive, whether
competitive athletes or not, need a thorough but directed
history and physical examination with a minimal number
of laboratory tests. The history should be sure to determine
whether the person has a family history of hypertension or
cardiovascular disease, symptoms suggestive of a pheo-
chromocytoma (paroxysmal hypertension, headache,
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2395diaphoresis, and palpitations) or if he or she uses nonste-
roidal anti-inﬂammatory agents or street drugs, especially
cocaine or amphetamines. Use of nonsteroidal anti-
inﬂammatory agents is particularly common among com-
petitive athletes, who often have minor injuries for which
these analgesic agents are beneﬁcial and available without
a prescription. Amphetamines are used to increase mental
alertness and decrease fatigue (11). Participation in certain
extracurricular activities, such as high-contact sports, may
inﬂuence male participants to misuse prescription stimu-
lants as performance enhancers either on or off the playing
ﬁeld. However, the use of these agents is notmore common
in competitive athletes than in the general population.
Although anabolic steroid abuse is becoming increasingly
uncommon in athletes in competitive sports, an analysis of
existing evidence suggests that chronic anabolic steroid
use does have a negative impact on lipoproteins and BP in
athletes (12).
The physical examination should be used to look for clues
to an identiﬁable cause of hypertension (so-called secondary
hypertension) such as abdominal bruits, which may indicate
the presence of renal artery stenosis and renovascular
hypertension, or a cushingoid body habitus or abdominal
striae suggesting adrenocortical hormonal excess. The
laboratory tests should also be limited to assessing the
presence of other cardiovascular risk factors such as dysli-
pidemias, glucose intolerance, and diabetes mellitus, and
particularly chronic renal disease, a problem common
among young black men and that is often asymptomatic
until its later stages. All competitive athletes should have a
lipid proﬁle (total cholesterol, high-density lipoprotein
cholesterol, and serum triglycerides) performed; fasting
serum glucose, electrolytes, and hemoglobin measured;
and urinary protein estimated by dipstick (3,13). Although it
is usually recommended that a lipid proﬁle and glucose
determination should be obtained after at least a 9-hour
fast, this may be logistically difﬁcult. Having the blood
drawn in the athletes in a fasting statemay not be feasible in
most circumstances, and it may be more reasonable to
obtain the samples when convenient and only repeat the
test in the fasting state when it is abnormal (13).
A 12-lead ECG is recommended but not mandated to
ascertain the presence of LVH or conduction abnormalities,
although the yield will be small. In those people with stage 2
hypertension (a systolic BP >160 mm Hg or a diastolic BP
>100 mm Hg) or who have a suggestion of target-organ
damage on history or physical examination, a screening
echocardiogram is advisable to distinguish physiological
hypertrophy attributable to physical exercise (athlete’s
heart) versus pathological LVH from hypertension. Athletes
with normal (or physiological) hypertrophy have echocar-
diographic and other imaging evidence of increased poste-
rior and septal wall thicknesses with normal cavity chamber
size accompanied by normal rates of left ventricular ﬁllingduring diastole (14); in contrast, hypertrophy caused by
hypertension, although having similar structural ﬁndings,
has both impaired rates of left ventricular ﬁlling and
slow isovolumic relaxation times (15). If needed, the
pathophysiology of cardiac hypertrophy attributable to
physiological causes versus pathophysiological causes
(hypertension) can be discriminated with echocardiogra-
phy using Doppler imaging or magnetic resonance imaging
as a tertiary methodology. People with larger body size and
blacks may have an increase in wall thicknesses on echo-
cardiography, which should be correlatedwith ECG, clinical
signs and symptoms, and family history before they are
advised against participation in competitive sports. It is rare
for physiological increased left ventricular wall thicknesses
to exceed 13mm and indicates the advisability of a referring
the patient for further evaluation for hypertrophic cardio-
myopathy with ECG, clinical assessment, and family his-
tory. Of note, LVH is more prevalent in blacks and is an
independent predictor of diminished cardiovascular sur-
vival (16). The ECG iswidely available, inexpensive, and has
high speciﬁcity but poor sensitivity for detection of LVH;
however, the combination of an abnormal ECG, any signs
and symptoms of heart disease, and a positive family his-
tory for premature cardiac death warrants further evalua-
tion. Cardiac stress testing is not warranted unless there are
symptoms that occur with maximal exercise. The competi-
tive athlete need not routinely require orthostatic BP de-
terminations unless the athlete is symptomatic in the
upright position in a volume replete state.
In an adolescent or young adult (i.e., <25 years of age)
with stage 2 hypertension, it may be appropriate to refer
this person for further evaluation and therapy to a
cardiologist or hypertension specialist. The workup for
secondary forms of hypertension and proper pharmaco-
logical management is often outside the scope of general
pediatricians and family practitioners who might other-
wise be seeing these athletes.
EFFECTS OF EXERCISE ON BP
Both systolic and diastolic BP rise during resistance (static
or isometric) exercise, and strenuous aerobic or resistance
exertion may precipitate myocardial infarction and sud-
den death in susceptible, untrained people. In the long
term, both systolic and diastolic BPs are lower with aer-
obic (dynamic) exercise and remain lower for up to
24 hours (17). In a person with normal BP at rest, a rise in
systolic BP to >200 mm Hg during an exercise treadmill
test may suggest underlying hypertension. This person
may beneﬁt from further investigation, including 24-hour
ambulatory BP monitoring, to document true sustained
hypertension (18). A hypertensive responsive to exercise
testing may also indicate an independent risk for cardio-
vascular events and mortality (19).
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1. It is reasonable that the presence of stage 1 hyper-
tension in the absence of target-organ damage should
not limit the eligibility for any competitive sport.
Once having begun a training program, the hyper-
tensive athlete should have BP measured every 2 to 4
months (or more frequently, if indicated) to monitor
the impact of exercise (Class I; Level of Evidence B).
2. Before people begin training for competitive athletics,
it is reasonable that they undergo careful assessment of
BP, and those with initially high levels (>140 mm Hg
systolic or >90 mm Hg diastolic) should have compre-
hensive out-of-ofﬁce measurements to exclude errors
in diagnosis. Ambulatory BP monitoring with proper
cuff and bladder size would be the most precise means
of measurement (Class I; Level of Evidence B).
3. Those with prehypertension (BP of 120/80 mm Hg–
139/89 mm Hg) should be encouraged to modify their
lifestyles but should not be restricted from physical
activity. Those with sustained hypertension should
have screening echocardiography performed. Athletes
with LVH beyond that seen with “athlete’s heart”Writing Group Disclosures
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